Page last updated: 2024-10-15

rhamnogalacturonan i

Description

rhamnogalacturonan I: pectic polysaccharide from sycamore cell walls; composed of galactosyluronic acid, rhamnosyl, galactosyl, arabinosyl & fucosyl residues [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

rhamnogalacturonan I : A family of polysaccharides that all contain a linear backbone composed of repeating units of the disaccharide alpha-D-GalpA-(l->2)-alpha-L-Rhap joined by alpha-(1->4) linkages. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID131801240
CHEBI ID139158
MeSH IDM0125458

Synonyms (2)

Synonym
CHEBI:139158
rhamnogalacturonan i

Research Excerpts

Overview

Rhamnogalacturonan I (RG-I) is a major plant cell wall pectic polysaccharide. It has a backbone of alternating rhamnose and galacturonic acid residues with side chains containing galactose and/or arabinose residues.

ExcerptReference
"Rhamnogalacturonan I (RG-I) is a major plant cell wall pectic polysaccharide defined by its repeating disaccharide backbone structure of [4)-α-D-GalA-(1,2)-α-L-Rha-(1,]. "( Polymerization of the backbone of the pectic polysaccharide rhamnogalacturonan I.
Amos, RA; Atmodjo, MA; Gao, Z; Huang, C; Kannan, N; Mohnen, D; Moremen, KW; Taujale, R; Venkat, A, 2022
)
"Rhamnogalacturonan I (RG-I) is a domain of plant cell wall pectin. "( Functional analysis of tomato rhamnogalacturonan lyase gene Solyc11g011300 during fruit development and ripening.
Báez-Sañudo, R; Berumen-Varela, G; Burgara-Estrella, A; Datsenka, T; Handa, AK; Ochoa-Jiménez, VA; Ojeda-Contreras, ÁJ; Orozco-Avitia, JA; Rivera-Domínguez, M; Tiznado-Hernández, ME; Trillo-Hernández, EA; Troncoso-Rojas, R, 2018
)
"Rhamnogalacturonan I (RG-I) is a highly structurally heterogeneous branched glycan domain within the pectic supramolecule that contains rhamnogalacturonan, arabinan and galactan as structural elements."( Multi-scale spatial heterogeneity of pectic rhamnogalacturonan I (RG-I) structural features in tobacco seed endosperm cell walls.
Cornuault, V; Knox, JP; Lee, KJ; Manfield, IW; Ralet, MC, 2013
)
"Rhamnogalacturonan I (RGI) is a pectic polysaccharide composed of a backbone of alternating rhamnose and galacturonic acid residues with side chains containing galactose and/or arabinose residues. "( The Deconstruction of Pectic Rhamnogalacturonan I Unmasks the Occurrence of a Novel Arabinogalactan Oligosaccharide Epitope.
Alvarado, C; Bouchet, B; Buffetto, F; Cornuault, V; Echasserieau, V; Guillon, F; Knox, JP; Le Gall, S; Ralet, MC; Ropartz, D; Rydahl, MG; Tranquet, O; Verhertbruggen, Y; Willats, WG, 2015
)

Effects

ExcerptReference
"Rhamnogalacturonan I (RG-I) has been isolated from the walls of suspension-cultured sycamore cells (Acer pseudoplatanus), and additional structural features of the polysaccharide were elucidated. "( Structural characterization of endo-glycanase-generated oligoglycosyl side chains of rhamnogalacturonan I.
Albersheim, P; Darvill, AG; Lerouge, P; O'Neill, MA, 1993
)

Toxicity

ExcerptReference
" cRG-I induced no adverse effects in this study."( Safety assessment of rhamnogalacturonan-enriched carrot pectin fraction: 90-Day oral toxicity study in rats and in vitro genotoxicity studies.
Albers, R; Aparicio-Vergara, M; Fowler, P; Jonker, D; Tzoumaki, MV; van Het Hof, KH, 2020
)

Bioavailability

ExcerptReference
" The low molecular weight of MTrPP (155kDa; TrPP-13kDa) may increase its bioavailability than TrPP, thus MTrPP may possess higher antiulcer potential."( Modified pectic polysaccharide from turmeric (Curcuma longa): A potent dietary component against gastric ulcer.
Chandra Prakash, SV; Dharmesh, SM; Harsha, MR, 2016
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (217)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (0.92)18.7374
1990's12 (5.53)18.2507
2000's44 (20.28)29.6817
2010's121 (55.76)24.3611
2020's38 (17.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.90%)5.53%
Reviews10 (4.52%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other209 (94.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]